On the morning of December 3, 2025, Ms. Feng Lan, Vice President of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), met with Mr. Ronald T. Piervincenzi, Chief Executive Officer (CEO) of the U.S. Pharmacopeia (USP), Dr. Geoff Tsen, USP Global Vice President and General Manager of Greater China, and other representatives of USP delegation. The two sides conducted in-depth discussions on topics including the development of international standards and the enhancement of innovative drug R&D capabilities.

Plenary Meeting

Ms. Feng Lan extended a warm welcome to the USP delegation. She highly recognized USP’s important contributions to the development of public quality standards, support for regulatory confidence, and acceleration of approval processes. As a think-tank association for the development of China’s pharmaceutical innovation, PhIRDA has always been committed to promoting the optimization of industrial structure and the improvement of the innovation policy environment, with its membership system covering the entire industrial chain of innovative drug R&D. In recent years, by building international exchange platforms, organizing policy seminars, and participating in the formulation of global rules, PhIRDA has facilitated Chinese pharmaceutical enterprises in accelerating their internationalization process. A number of PhIRDA members have established in-depth cooperation with USP, actively participating in the development of relevant standards and promoting the internationalization of pharmaceutical quality standards.

Mr. Piervincenzi commended the remarkable contribution in China’s pharmaceutical innovation industry and spoke highly of PhIRDA’s important role in advancing the internationalization of China’s pharmaceutical industry. He provided a detailed overview of the global application status of USP standards, the history of cooperation with China, USP’s core functions, and its 2030 Commitments. Founded in 1820, USP has developed standards that serve as important global references for pharmaceutical quality and are used in more than 150 countries. USP has maintained long-term and close cooperation with China’s pharmaceutical regulatory authorities, inspection institutions, and pharmaceutical enterprises. Among USP’s over 450 global member organizations, the number of Chinese organizations ranks second only to those in the United States. Through joint standard development, professional training conferences, and other initiatives, USP and Chinese member organizations have provided strong support for the high-quality development of the global pharmaceutical industry. Looking ahead, USP will continue to empower pharmaceutical innovation through standardization, and looks forward to conducting in-depth cooperation with PhIRDA to support Chinese innovative drugs to enter the international market, continuously improve pharmaceutical quality, and to contribute more to global drug safety and improve the health of people around the world.

Both parties agreed that further enhancing Chinese innovative pharmaceutical enterprises’ understanding and application of USP standards is of great significance for promoting the internationalization of China’s innovative pharmaceutical industry. Leveraging PhIRDA’s platform advantages and expert resources, the two sides will carry out in-depth cooperation in areas including innovative drug R&D, cell and gene therapy, and pharmaceutical regulatory policies. They will focus on the early-stage standard development for innovative drugs, promote the collaborative development of international standards, take standards as the guide to advance innovative drug R&D, address technical challenges in innovative drug R&D, making positive contributions to integrating China’s pharmaceutical innovation industry into the global regulatory system and enhancing its international competitiveness. Ms. Lu Xiaoti, Deputy Secretary-General of PhIRDA, Ms. Ruan Xinxin, Director of International Cooperation Department of PhIRDA; Mr. Kevin Cao, Senior Director of USP SCD team, Greater China, Ms. Xiao Ling, Director of External Affairs, USP Greater China, and Mr. Wenjun Cao, Senior Manager of USP SCD team, Greater China，attended the meeting.

Group Photo

(From left to right: Geoff Tsen, FENG Lan, Ronald T. Piervincenzi, LU Xiaoti)

Introduction of U.S. Pharmacopeia

U.S. Pharmacopeia (USP), founded in 1820, is an independent, scientific nonprofit organization focused on building trust in the supply of safe, quality medicines. For over 200 years, USP has worked to build trust where it matters most: in the world’s medicines, dietary supplements and foods, and has always pursued the mission of improving the health of people around the world. Through the rigorous science and the public quality standards we set, USP helps ensure the quality, safety and efficacy of pharmaceuticals and foods. Nearly 1,000 volunteer experts from diverse fields around the globe participate in its standard-setting work, laying a solid foundation of trust for the global supply of safe and high-quality medical and health products, and helping protect patient safety and improve the health of people around the world.